Agilo Luitger Kern
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Agilo Luitger Kern has a total of 106 co-authors. Here are the top co-authors by number of shared publications:
Frank Wacker
Institute for Diagnostic and Interventional Radiology, Hannover Medical School Hannover Germany
18 shared publications- Jens Vogel-Claussen
Department of Diagnostic and Interventional Radiology, Hannover Medical School, Hannover, Germany
14 shared publications Marcel Gutberlet
Institute for Diagnostic and Interventional Radiology, Hannover Medical School Hannover Germany
13 shared publicationsAndreas Voskrebenzev
Institute of Diagnostic and Interventional Radiology, Hannover Medical School Hannover Germany
11 shared publicationsJens M. Hohlfeld
Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH) German Center for Lung Research (DZL) Hannover Germany
10 shared publicationsFilip Klimeš
Institute for Diagnostic and Interventional Radiology, Hannover Medical School; Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), German Center for Lung Research (DZL), Hannover, Germany
8 shared publications
Latest Publications
- Open Access
- 23 September 2026
- Published by Wiley in Journal of Magnetic Resonance Imaging
Effects of Single and Multiple Dose Tiotropium/Olodaterol in Chronic Obstructive Pulmonary Disease on Alveolar Gas Exchange Measured by Hyperpolarized 129 Xe MRI
Background: Long‐acting muscarinic antagonists/long‐acting beta adrenoreceptor agonists lead to lung deflation and improved microvascular perfusion in hyperinflated chronic obstructive pulmonary disease (COPD), but with an unclear time course. Purpose: To investigate the effect of inhalation of tiotropium/olodaterol (TIO/OLO) on MRI measures of gas uptake and microvascular blood volume after single and multiple doses. Study Type: Prospective, randomized, investigator‐blinded, placebo‐controlled single‐dose crossover study with open‐label multiple‐dose extension. Population: 31 participants with COPD and lung hyperinflation (residual volume > 135% predicted, ≥ 10 pack‐years smoking). Fieldstrength/Sequence: 1.5 T/Interleaved 3D radial gas and dissolved‐phase MRI using multi‐echo FLASH, high‐resolution spectroscopy, chemical shift saturation recovery spectroscopy. Assessment: Ratios of 129 Xe in membrane tissues (M) to gas (M‐Gas), red blood cells (RBC) to gas (RBC‐Gas), RBC to M (RBC‐M) were calculated from dissolved‐phase imaging. Dissolved‐phase apparent transverse relaxation times (T 2 *) from high‐resolution spectra were also calculated, and septal wall thickness and surface‐volume ratio (S/V) were assessed by fitting a model of xenon exchange functions. Parameters were compared for single‐dose (5 μg/5 μg TIO/OLO) versus placebo using saline, and single‐dose versus multiple‐dose (daily 5 μg/5 μg TIO/OLO for 14 days) treatments. Statistical Tests: Linear mixed models with contrasts of estimated marginal means, significance level 0.05. Results: Compared with placebo, single‐dose treatment significantly increased RBC‐Gas and septal thickness but not RBC‐M ( p = 0.06), M‐Gas ( p = 0.16), RBC T 2 * ( p = 0.13), M T 2 * ( p = 0.09) and S/V ( p = 0.47). Multiple‐dose treatment significantly increased RBC‐Gas, M‐Gas and M T 2 * compared with single‐dose treatment, but not RBC‐M ( p = 0.82), RBC T 2 * ( p = 0.48), septal thickness ( p = 0.61), and S/V ( p = 0.49). Data Conclusion: Single‐dose TIO/OLO increased 129 Xe in RBC‐Gas. Multiple‐dose treatment increased M‐Gas and further increased RBC‐Gas compared to single‐dose treatment. Technical Efficacy: Stage 4. Evidence Level: 2.
- 23 September 2026
- Published by Wiley in Journal of Magnetic Resonance Imaging
Open AccessEffects of Single and Multiple Dose Tiotropium/Olodaterol in Chronic Obstructive Pulmonary Disease on Alveolar Gas Exchange Measured by Hyperpolarized 129 Xe MRI
Background: Long‐acting muscarinic antagonists/long‐acting beta adrenoreceptor agonists lead to lung deflation and improved microvascular perfusion in hyperinflated chronic obstructive pulmonary disease (COPD), but with an unclear time course. Purpose: To investigate the effect of inhalation of tiotropium/olodaterol (TIO/OLO) on MRI measures of gas uptake and microvascular blood volume after single and multiple doses. Study Type: Prospective, randomized, investigator‐blinded, placebo‐controlled single‐dose crossover study with open‐label multiple‐dose extension. Population: 31 participants with COPD and lung hyperinflation (residual volume > 135% predicted, ≥ 10 pack‐years smoking). Fieldstrength/Sequence: 1.5 T/Interleaved 3D radial gas and dissolved‐phase MRI using multi‐echo FLASH, high‐resolution spectroscopy, chemical shift saturation recovery spectroscopy. Assessment: Ratios of 129 Xe in membrane tissues (M) to gas (M‐Gas), red blood cells (RBC) to gas (RBC‐Gas), RBC to M (RBC‐M) were calculated from dissolved‐phase imaging. Dissolved‐phase apparent transverse relaxation times (T 2 *) from high‐resolution spectra were also calculated, and septal wall thickness and surface‐volume ratio (S/V) were assessed by fitting a model of xenon exchange functions. Parameters were compared for single‐dose (5 μg/5 μg TIO/OLO) versus placebo using saline, and single‐dose versus multiple‐dose (daily 5 μg/5 μg TIO/OLO for 14 days) treatments. Statistical Tests: Linear mixed models with contrasts of estimated marginal means, significance level 0.05. Results: Compared with placebo, single‐dose treatment significantly increased RBC‐Gas and septal thickness but not RBC‐M ( p = 0.06), M‐Gas ( p = 0.16), RBC T 2 * ( p = 0.13), M T 2 * ( p = 0.09) and S/V ( p = 0.47). Multiple‐dose treatment significantly increased RBC‐Gas, M‐Gas and M T 2 * compared with single‐dose treatment, but not RBC‐M ( p = 0.82), RBC T 2 * ( p = 0.48), septal thickness ( p = 0.61), and S/V ( p = 0.49). Data Conclusion: Single‐dose TIO/OLO increased 129 Xe in RBC‐Gas. Multiple‐dose treatment increased M‐Gas and further increased RBC‐Gas compared to single‐dose treatment. Technical Efficacy: Stage 4. Evidence Level: 2.
- Open Access
- 5 July 2026
- Published by Wiley in Magnetic Resonance in Medicine
- Vol. 96 (5) , 2201-2212
Feasibility and SNR Performance of Hyperpolarized 129 Xe Gas Exchange Imaging Using a Balanced SSFP Sequence
Purpose: To develop a balanced SSFP (bSSFP) sequence for pulmonary 129 Xe dissolved‐phase imaging based on a previously described double‐echo sequence facilitating separation into red blood cell and membrane signals, to test its feasibility and compare its SNR performance and imaging results to an analogous FLASH sequence. Methods: 12 healthy volunteers underwent hyperpolarized 129 Xe MRI with both sequences with two different choices of flip angle for FLASH. SNR was quantified using a pseudo multiple replica method, normalized by 129 Xe polarization and ventilated volume. Chemical shift separation was performed in k‐space taking results from time‐domain fits of signal evolution as input, either approximating T E as constant or taking the finite readout duration into account. Results were compared between sequences and methods by linear mixed models, Bland–Altman, and scatter plots. Results: Normalized SNR of the first echo was significantly greater for bSSFP compared to FLASH with the same flip angle, p = 0.003, but not with lower flip angle resulting in equivalent depolarization, p = 0.98. The effective number of signal averages in signal decomposition was significantly higher compared to FLASH with both flip angles and both dissolved resonances, p < 0.008. Neglecting the finite readout duration was found to introduce bias of derived RBC‐M ratios but prevent noise amplification. Conclusion: Hyperpolarized 129 Xe dissolved‐phase imaging using dual‐echo bSSFP is feasible and provides superior effective number of signal averages resulting in improved SNR efficiency of signal decomposition. Future work should concentrate on the application in patients with lung disease.
- 5 July 2026
- Published by Wiley in Magnetic Resonance in Medicine
- Vol. 96 (5) , 2201-2212
Open AccessFeasibility and SNR Performance of Hyperpolarized 129 Xe Gas Exchange Imaging Using a Balanced SSFP Sequence
Purpose: To develop a balanced SSFP (bSSFP) sequence for pulmonary 129 Xe dissolved‐phase imaging based on a previously described double‐echo sequence facilitating separation into red blood cell and membrane signals, to test its feasibility and compare its SNR performance and imaging results to an analogous FLASH sequence. Methods: 12 healthy volunteers underwent hyperpolarized 129 Xe MRI with both sequences with two different choices of flip angle for FLASH. SNR was quantified using a pseudo multiple replica method, normalized by 129 Xe polarization and ventilated volume. Chemical shift separation was performed in k‐space taking results from time‐domain fits of signal evolution as input, either approximating T E as constant or taking the finite readout duration into account. Results were compared between sequences and methods by linear mixed models, Bland–Altman, and scatter plots. Results: Normalized SNR of the first echo was significantly greater for bSSFP compared to FLASH with the same flip angle, p = 0.003, but not with lower flip angle resulting in equivalent depolarization, p = 0.98. The effective number of signal averages in signal decomposition was significantly higher compared to FLASH with both flip angles and both dissolved resonances, p < 0.008. Neglecting the finite readout duration was found to introduce bias of derived RBC‐M ratios but prevent noise amplification. Conclusion: Hyperpolarized 129 Xe dissolved‐phase imaging using dual‐echo bSSFP is feasible and provides superior effective number of signal averages resulting in improved SNR efficiency of signal decomposition. Future work should concentrate on the application in patients with lung disease.
- Open Access
- 31 January 2026
- Published by Wiley in Journal of Magnetic Resonance Imaging
- Vol. 63 (5) , 1420-1432
Analysis of Pulsatile Vessel Expansion in Healthy, COPD ‐ and PH ‐Patients Using Dynamic Vessel Segmentation in Free‐Breathing Lung MRI
Background: The pulsatile expansion of pulmonary vessels carries dynamic cardiopulmonary information that may reveal disease earlier than structural changes alone. Purpose: To test (i) intra‐ and inter‐scan repeatability of dynamic vessel metrics in healthy subjects, and (ii) whether chronic obstructive pulmonary disease (COPD) and postcapillary pulmonary hypertension (PH) exhibit disease‐specific differences. Study Type: Retrospective, multi‐cohort feasibility study with repeatability sub‐study. Subjects: Healthy: 29 (11 female), COPD: 52 (15 female), PH: 25 (15 female) with isolated postcapillary PH. Fieldstrength/Sequence: 1.5T, free‐breathing spoiled gradient‐echo sequence, TE = 0.82 ms, TR = 3 ms, flip angle = 5°. Assessment: 2D U‐Nets segmented pulmonary vessels throughout each series of 250 images. Dynamic metrics included the coefficient of variation (CV) of vessel area and CV of vessel signal. Delay between vessel signal and vessel expansion as %‐of‐RR‐interval (SE‐delay) together with the heart rate and lung area were calculated. Statistical Tests: Repeatability: Friedman; intraclass correlation coefficient (ICC); standard error of measurement (SEM) and the minimal detectable change (MDC). Group comparisons: Kruskal–Wallis and multiple linear regression. p < 0.05 was considered significant. Results: Only the heart rate and the SE‐delay presented significant changes across repetitive scans. Differences in Bland–Altman plots were evenly distributed across the range of measurements and symmetrically scattered around zero within 95% confidence intervals (mean bias 0.08%–5.12%). Across cohorts, CV vessel area and CV lung area differed significantly, showing lowest variability in COPD (2.67%; 7.03%) and highest in PH (4.58%; 16.74%). SE‐delay was significantly prolonged in COPD (81.98%) compared to PH (67.20%) and healthy participants (62.97%). Cohort status (Healthy/COPD/PH) remained the strongest significant predictor for all parameters after adjustment ( F ‐values 4.62–34.04), while age and gender had no significant influence ( p > 0.391; p > 0.069). Data Conclusion: Free‐breathing lung MRI with automated vessel segmentation reveals distinct hemodynamic characteristics in COPD and PH. This method shows potential as a sensitive non‐invasive tool for detection, phenotyping, and treatment monitoring in pulmonary pathology. Evidence Level: 3. Technical Efficacy: 2.
- 31 January 2026
- Published by Wiley in Journal of Magnetic Resonance Imaging
- Vol. 63 (5) , 1420-1432
Open AccessAnalysis of Pulsatile Vessel Expansion in Healthy, COPD ‐ and PH ‐Patients Using Dynamic Vessel Segmentation in Free‐Breathing Lung MRI
Background: The pulsatile expansion of pulmonary vessels carries dynamic cardiopulmonary information that may reveal disease earlier than structural changes alone. Purpose: To test (i) intra‐ and inter‐scan repeatability of dynamic vessel metrics in healthy subjects, and (ii) whether chronic obstructive pulmonary disease (COPD) and postcapillary pulmonary hypertension (PH) exhibit disease‐specific differences. Study Type: Retrospective, multi‐cohort feasibility study with repeatability sub‐study. Subjects: Healthy: 29 (11 female), COPD: 52 (15 female), PH: 25 (15 female) with isolated postcapillary PH. Fieldstrength/Sequence: 1.5T, free‐breathing spoiled gradient‐echo sequence, TE = 0.82 ms, TR = 3 ms, flip angle = 5°. Assessment: 2D U‐Nets segmented pulmonary vessels throughout each series of 250 images. Dynamic metrics included the coefficient of variation (CV) of vessel area and CV of vessel signal. Delay between vessel signal and vessel expansion as %‐of‐RR‐interval (SE‐delay) together with the heart rate and lung area were calculated. Statistical Tests: Repeatability: Friedman; intraclass correlation coefficient (ICC); standard error of measurement (SEM) and the minimal detectable change (MDC). Group comparisons: Kruskal–Wallis and multiple linear regression. p < 0.05 was considered significant. Results: Only the heart rate and the SE‐delay presented significant changes across repetitive scans. Differences in Bland–Altman plots were evenly distributed across the range of measurements and symmetrically scattered around zero within 95% confidence intervals (mean bias 0.08%–5.12%). Across cohorts, CV vessel area and CV lung area differed significantly, showing lowest variability in COPD (2.67%; 7.03%) and highest in PH (4.58%; 16.74%). SE‐delay was significantly prolonged in COPD (81.98%) compared to PH (67.20%) and healthy participants (62.97%). Cohort status (Healthy/COPD/PH) remained the strongest significant predictor for all parameters after adjustment ( F ‐values 4.62–34.04), while age and gender had no significant influence ( p > 0.391; p > 0.069). Data Conclusion: Free‐breathing lung MRI with automated vessel segmentation reveals distinct hemodynamic characteristics in COPD and PH. This method shows potential as a sensitive non‐invasive tool for detection, phenotyping, and treatment monitoring in pulmonary pathology. Evidence Level: 3. Technical Efficacy: 2.
- Open Access
- 30 January 2026
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 12 (3)
Acute and 14-day effects of tiotropium/olodaterol on cardiopulmonary function in COPD
Background: Lung hyperinflation in COPD adversely affects cardiac function and may influence autonomic nervous system activity. The onset of cardiac improvement with dual bronchodilator therapy remains uncertain. Methods: In this randomised, placebo-controlled, investigator-blinded, mechanistic, single-dose crossover trial with an open-label 2-week extension we assessed tiotropium/olodaterol (T/O) effects on cardiopulmonary function and muscle sympathetic nerve activity (MSNA) in hyperinflated COPD patients. 32 participants received saline (placebo) and T/O (5 µg/5 µg) in a crossover design, followed by 14 days of open-label T/O. The primary end-point was change in left ventricular end-diastolic volume index (LV-EDVi) measured by magnetic resonance imaging (MRI). Secondary assessments included pulmonary function tests, MSNA measurements and advanced lung imaging including 129 Xe-MRI. Findings: Single-dose T/O significantly increased LV-EDVi relative to placebo (3.25 mL·m −2 ; 95% CI 0.95 to 5.56), driven partly by a decrease under placebo. Compared with baseline, T/O's acute LV-EDVi gain was minimal, yet it reached significance at 14 days (4.70 mL·m −2 ; 95% CI 1.75 to 7.65). Pulmonary parameters, in contrast, showed immediate improvement, with a marked reduction in residual volume (−0.67 L; 95% CI −0.82 to −0.51) after a single dose. MSNA demonstrated a nonsignificant numerical rise post single-dose T/O. No serious adverse events occurred. Interpretation: T/O rapidly improves pulmonary function in hyperinflated COPD patients, but significant cardiac benefits seem to require sustained therapy. These results underscore the importance of continued dual bronchodilator therapy to achieve cardiovascular improvements. The nonsignificant rise in MSNA after a single dose suggests minimal immediate effect on sympathetic activity; further studies are necessary to evaluate long-term autonomic outcomes.
- 30 January 2026
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 12 (3)
Open AccessAcute and 14-day effects of tiotropium/olodaterol on cardiopulmonary function in COPD
Background: Lung hyperinflation in COPD adversely affects cardiac function and may influence autonomic nervous system activity. The onset of cardiac improvement with dual bronchodilator therapy remains uncertain. Methods: In this randomised, placebo-controlled, investigator-blinded, mechanistic, single-dose crossover trial with an open-label 2-week extension we assessed tiotropium/olodaterol (T/O) effects on cardiopulmonary function and muscle sympathetic nerve activity (MSNA) in hyperinflated COPD patients. 32 participants received saline (placebo) and T/O (5 µg/5 µg) in a crossover design, followed by 14 days of open-label T/O. The primary end-point was change in left ventricular end-diastolic volume index (LV-EDVi) measured by magnetic resonance imaging (MRI). Secondary assessments included pulmonary function tests, MSNA measurements and advanced lung imaging including 129 Xe-MRI. Findings: Single-dose T/O significantly increased LV-EDVi relative to placebo (3.25 mL·m −2 ; 95% CI 0.95 to 5.56), driven partly by a decrease under placebo. Compared with baseline, T/O's acute LV-EDVi gain was minimal, yet it reached significance at 14 days (4.70 mL·m −2 ; 95% CI 1.75 to 7.65). Pulmonary parameters, in contrast, showed immediate improvement, with a marked reduction in residual volume (−0.67 L; 95% CI −0.82 to −0.51) after a single dose. MSNA demonstrated a nonsignificant numerical rise post single-dose T/O. No serious adverse events occurred. Interpretation: T/O rapidly improves pulmonary function in hyperinflated COPD patients, but significant cardiac benefits seem to require sustained therapy. These results underscore the importance of continued dual bronchodilator therapy to achieve cardiovascular improvements. The nonsignificant rise in MSNA after a single dose suggests minimal immediate effect on sympathetic activity; further studies are necessary to evaluate long-term autonomic outcomes.
- Open Access
- 11 April 2025
- Published by Wiley in Journal of Magnetic Resonance Imaging
- Vol. 62 (4) , 986-1008
Functional Pulmonary Imaging
The aging of the world population gave rise to an increased prevalence of many lung diseases, with chronic obstructive pulmonary disease now ranking as the third‐leading cause of death according to the World Health Organization. To diagnose lung disease, a thorough assessment of lung function is essential since it may reveal unique signatures in terms of disease pathophysiology. Yet, clinically established lung function tests are global measurements, which may compromise their sensitivity to early, regional changes in lung function compared to spatially resolved imaging tests. From a scientific perspective, the lung is a highly complex organ, and newly developed functional imaging methods may elucidate previously unknown aspects of its physiology. Functional pulmonary imaging is and will thus be of great value for both clinical and research applications. The goal of this review is to shed light on the field of functional pulmonary imaging in all its varieties, with a particular focus on the numerous tools MRI has to offer. This includes 1H MRI methods with or without exogenous contrast agents like oxygen‐ or gadolinium‐based contrast agents and MRI of hyperpolarized and inert gases like 129Xe or perfluoropropane. However, thinking outside the box, a glance is also taken at what other modalities like single‐photon emission computed tomography, computed tomography, or X‐ray dark‐field imaging have to offer. Following a physiological perspective, methods are described in terms of their ability to assess the key parameters of lung physiology in humans—ventilation, perfusion, and alveolar membrane function, as well as microstructure—and promising clinical and research applications are discussed. An outlook into possible future paths the field might take is given. Evidence Level: 5. Technical Efficacy: 2.
- 11 April 2025
- Published by Wiley in Journal of Magnetic Resonance Imaging
- Vol. 62 (4) , 986-1008
Open AccessFunctional Pulmonary Imaging
The aging of the world population gave rise to an increased prevalence of many lung diseases, with chronic obstructive pulmonary disease now ranking as the third‐leading cause of death according to the World Health Organization. To diagnose lung disease, a thorough assessment of lung function is essential since it may reveal unique signatures in terms of disease pathophysiology. Yet, clinically established lung function tests are global measurements, which may compromise their sensitivity to early, regional changes in lung function compared to spatially resolved imaging tests. From a scientific perspective, the lung is a highly complex organ, and newly developed functional imaging methods may elucidate previously unknown aspects of its physiology. Functional pulmonary imaging is and will thus be of great value for both clinical and research applications. The goal of this review is to shed light on the field of functional pulmonary imaging in all its varieties, with a particular focus on the numerous tools MRI has to offer. This includes 1H MRI methods with or without exogenous contrast agents like oxygen‐ or gadolinium‐based contrast agents and MRI of hyperpolarized and inert gases like 129Xe or perfluoropropane. However, thinking outside the box, a glance is also taken at what other modalities like single‐photon emission computed tomography, computed tomography, or X‐ray dark‐field imaging have to offer. Following a physiological perspective, methods are described in terms of their ability to assess the key parameters of lung physiology in humans—ventilation, perfusion, and alveolar membrane function, as well as microstructure—and promising clinical and research applications are discussed. An outlook into possible future paths the field might take is given. Evidence Level: 5. Technical Efficacy: 2.
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , OA5465
129Xe magnetic resonance imaging for monitoring lung function and microstructure in patients on treatment for progressive fibrosing interstitial lung disease
Introduction: Novel antifibrotic therapy slows down lung function decline in patients with progressive fibrosing ILD (PF-ILD). While traditional lung function measures like FVC have limited sensitivity for early lung function alterations, more sensitive biomarkers for assessment of fibrosis progression and efficacy of new treatments are desirable. Aims and Objectives: The aim was to investigate the potential of hyperpolarized 129Xe MR imaging markers for noninvasive assessment of disease progression in patients on antifibrotic therapy in an observational clinical trial. Methods: 14 PF-ILD patients underwent 129Xe MRI and lung function testing at baseline and 3 and 6 months post initiation of clinically indicated antifibrotic therapy. MRI included dissolved-phase spectroscopy with frequency-selective excitation increasing signal from red blood cells (RBC) relative to membrane (M) to obtain averaged RBC:M and chemical shift saturation recovery (CSSR) quantifying dynamic 129Xe uptake. CSSR data were analysed using MOXE to obtain surface-volume ratios (S/V). Results: Mean RBC:M was reduced at 6 months (P=0.01, –11%) and 3 months (P=0.04, –9%) vs. baseline. S/V was reduced at 6 months (P=0.007, –16%), but not 3 months (P=0.09, –13%). DLCO (mmol/min/kPa) was reduced at 6 (P=0.01, –10%), but not 3 months (P=0.76, –2%). FVC (L) did not change (6 months: P=0.81, –2%, 3 months: P=0.22, +2%). Conclusions: RBC:M seems more sensitive to early changes of alveolar membrane function than DLCO and FVC. S/V reduction is reflective of declining functional alveolar surface. RBC:M and S/V may be useful for monitoring PF-ILD patients on antifibrotic therapy.
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , OA5465
129Xe magnetic resonance imaging for monitoring lung function and microstructure in patients on treatment for progressive fibrosing interstitial lung disease
Introduction: Novel antifibrotic therapy slows down lung function decline in patients with progressive fibrosing ILD (PF-ILD). While traditional lung function measures like FVC have limited sensitivity for early lung function alterations, more sensitive biomarkers for assessment of fibrosis progression and efficacy of new treatments are desirable. Aims and Objectives: The aim was to investigate the potential of hyperpolarized 129Xe MR imaging markers for noninvasive assessment of disease progression in patients on antifibrotic therapy in an observational clinical trial. Methods: 14 PF-ILD patients underwent 129Xe MRI and lung function testing at baseline and 3 and 6 months post initiation of clinically indicated antifibrotic therapy. MRI included dissolved-phase spectroscopy with frequency-selective excitation increasing signal from red blood cells (RBC) relative to membrane (M) to obtain averaged RBC:M and chemical shift saturation recovery (CSSR) quantifying dynamic 129Xe uptake. CSSR data were analysed using MOXE to obtain surface-volume ratios (S/V). Results: Mean RBC:M was reduced at 6 months (P=0.01, –11%) and 3 months (P=0.04, –9%) vs. baseline. S/V was reduced at 6 months (P=0.007, –16%), but not 3 months (P=0.09, –13%). DLCO (mmol/min/kPa) was reduced at 6 (P=0.01, –10%), but not 3 months (P=0.76, –2%). FVC (L) did not change (6 months: P=0.81, –2%, 3 months: P=0.22, +2%). Conclusions: RBC:M seems more sensitive to early changes of alveolar membrane function than DLCO and FVC. S/V reduction is reflective of declining functional alveolar surface. RBC:M and S/V may be useful for monitoring PF-ILD patients on antifibrotic therapy.
- Open Access
- 9 March 2024
- Published by Springer Nature in European Radiology
- Vol. 34 (10) , 6502-6513
Alveolar membrane and capillary function in COVID-19 convalescents: insights from chest MRI
Objectives: To investigate potential presence and resolution of longer-term pulmonary diffusion limitation and microvascular perfusion impairment in COVID-19 convalescents. Materials and methods: This prospective, longitudinal study was carried out between May 2020 and April 2023. COVID-19 convalescents repeatedly and age/sex-matched healthy controls once underwent MRI including hyperpolarized 129Xe MRI. Blood samples were obtained in COVID-19 convalescents for immunophenotyping. Ratios of 129Xe in red blood cells (RBC), tissue/plasma (TP), and gas phase (GP) as well as lung surface-volume ratio were quantified and correlations with CD4+/CD8+ T cell frequencies were assessed using Pearson’s correlation coefficient. Signed-rank tests were used for longitudinal and U tests for group comparisons. Results: Thirty-five participants were recruited. Twenty-three COVID-19 convalescents (age 52.1 ± 19.4 years, 13 men) underwent baseline MRI 12.6 ± 4.2 weeks after symptom onset. Fourteen COVID-19 convalescents underwent follow-up MRI and 12 were included for longitudinal comparison (baseline MRI at 11.5 ± 2.7 weeks and follow-up 38.0 ± 5.5 weeks). Twelve matched controls were included for comparison. In COVID-19 convalescents, RBC-TP was increased at follow-up (p = 0.04). Baseline RBC-TP was lower in patients treated on intensive care unit (p = 0.03) and in patients with severe/critical disease (p = 0.006). RBC-TP correlated with CD4+/CD8+ T cell frequencies (R = 0.61/ − 0.60) at baseline. RBC-TP was not significantly different compared to matched controls at follow-up (p = 0.25). Conclusion: Impaired microvascular pulmonary perfusion and alveolar membrane function persisted 12 weeks after symptom onset and resolved within 38 weeks after COVID-19 symptom onset. Clinical relevance statement: 129Xe MRI shows improvement of microvascular pulmonary perfusion and alveolar membrane function between 11.5 ± 2.7 weeks and 38.0 ± 5.5 weeks after symptom onset in patients after COVID-19, returning to normal in subjects without significant prior disease. Key Points: • The study aims to investigate long-term effects of COVID-19 on lung function, in particular gas uptake efficiency, and on the cardiovascular system. • In COVID-19 convalescents, the ratio of 129Xe in red blood cells/tissue plasma increased longitudinally (p = 0.04), but was not different from matched controls at follow-up (p = 0.25). • Microvascular pulmonary perfusion and alveolar membrane function are impaired 11.5 weeks after symptom onset in patients after COVID-19, returning to normal in subjects without significant prior disease at 38.0 weeks.
- 9 March 2024
- Published by Springer Nature in European Radiology
- Vol. 34 (10) , 6502-6513
Open AccessAlveolar membrane and capillary function in COVID-19 convalescents: insights from chest MRI
Objectives: To investigate potential presence and resolution of longer-term pulmonary diffusion limitation and microvascular perfusion impairment in COVID-19 convalescents. Materials and methods: This prospective, longitudinal study was carried out between May 2020 and April 2023. COVID-19 convalescents repeatedly and age/sex-matched healthy controls once underwent MRI including hyperpolarized 129Xe MRI. Blood samples were obtained in COVID-19 convalescents for immunophenotyping. Ratios of 129Xe in red blood cells (RBC), tissue/plasma (TP), and gas phase (GP) as well as lung surface-volume ratio were quantified and correlations with CD4+/CD8+ T cell frequencies were assessed using Pearson’s correlation coefficient. Signed-rank tests were used for longitudinal and U tests for group comparisons. Results: Thirty-five participants were recruited. Twenty-three COVID-19 convalescents (age 52.1 ± 19.4 years, 13 men) underwent baseline MRI 12.6 ± 4.2 weeks after symptom onset. Fourteen COVID-19 convalescents underwent follow-up MRI and 12 were included for longitudinal comparison (baseline MRI at 11.5 ± 2.7 weeks and follow-up 38.0 ± 5.5 weeks). Twelve matched controls were included for comparison. In COVID-19 convalescents, RBC-TP was increased at follow-up (p = 0.04). Baseline RBC-TP was lower in patients treated on intensive care unit (p = 0.03) and in patients with severe/critical disease (p = 0.006). RBC-TP correlated with CD4+/CD8+ T cell frequencies (R = 0.61/ − 0.60) at baseline. RBC-TP was not significantly different compared to matched controls at follow-up (p = 0.25). Conclusion: Impaired microvascular pulmonary perfusion and alveolar membrane function persisted 12 weeks after symptom onset and resolved within 38 weeks after COVID-19 symptom onset. Clinical relevance statement: 129Xe MRI shows improvement of microvascular pulmonary perfusion and alveolar membrane function between 11.5 ± 2.7 weeks and 38.0 ± 5.5 weeks after symptom onset in patients after COVID-19, returning to normal in subjects without significant prior disease. Key Points: • The study aims to investigate long-term effects of COVID-19 on lung function, in particular gas uptake efficiency, and on the cardiovascular system. • In COVID-19 convalescents, the ratio of 129Xe in red blood cells/tissue plasma increased longitudinally (p = 0.04), but was not different from matched controls at follow-up (p = 0.25). • Microvascular pulmonary perfusion and alveolar membrane function are impaired 11.5 weeks after symptom onset in patients after COVID-19, returning to normal in subjects without significant prior disease at 38.0 weeks.
- 9 September 2023
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 62 (suppl 67) , OA744
Subtypes of pulmonary hypertension: gas uptake to lung capillaries and lung microstructure assessed by 129Xe MRI
Introduction: Previous studies suggest that IPAH consists of several phenotypes, some of them defined by higher/lower DLCO (IPAH-high/low) and less/more frequent smoking history in the absence of parenchymal lung disease apparent on CT. Aims and objectives: Aim was to evaluate 129Xe uptake to capillaries in patients with IPAH-high/low to test the hypothesis of loss of small pulmonary vessels in IPAH-low, to evaluate alveolar microstructure and to compare results to patients with combined pulmonary fibrosis and emphysema (CPFE) and upper-lobe emphysema (ULE). Methods: Patients underwent 129Xe MRI and CT. The 129Xe in red blood cells (RBC) fraction η in diffusional equilibrium and the RBC/tissue ratio were assessed from chemical shift saturation recovery and high-resolution spectra. 129Xe gas diffusion imaging and CT data were used to calculate apparent diffusivity (ADC) and low-attenuation area percentage (<–950HU, LAA%). Results: 21 patients with IPAH-high/IPAH-low/CPFE/ULE (5/4/6/6) were included. η and RBC/tissue were significantly reduced in IPAH-low compared to IPAH-high. ADC was significantly increased but LAA% was not (Figure). Conclusion: Reduction of η and RBC/tissue is consistent with a loss of functional pulmonary capillaries in IPAH-low. Alveolar microstructure destruction must be considered as contributing factor as evidenced by elevated 129Xe ADC, which seems more sensitive for emphysema than LAA%.
- 9 September 2023
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 62 (suppl 67) , OA744
Subtypes of pulmonary hypertension: gas uptake to lung capillaries and lung microstructure assessed by 129Xe MRI
Introduction: Previous studies suggest that IPAH consists of several phenotypes, some of them defined by higher/lower DLCO (IPAH-high/low) and less/more frequent smoking history in the absence of parenchymal lung disease apparent on CT. Aims and objectives: Aim was to evaluate 129Xe uptake to capillaries in patients with IPAH-high/low to test the hypothesis of loss of small pulmonary vessels in IPAH-low, to evaluate alveolar microstructure and to compare results to patients with combined pulmonary fibrosis and emphysema (CPFE) and upper-lobe emphysema (ULE). Methods: Patients underwent 129Xe MRI and CT. The 129Xe in red blood cells (RBC) fraction η in diffusional equilibrium and the RBC/tissue ratio were assessed from chemical shift saturation recovery and high-resolution spectra. 129Xe gas diffusion imaging and CT data were used to calculate apparent diffusivity (ADC) and low-attenuation area percentage (<–950HU, LAA%). Results: 21 patients with IPAH-high/IPAH-low/CPFE/ULE (5/4/6/6) were included. η and RBC/tissue were significantly reduced in IPAH-low compared to IPAH-high. ADC was significantly increased but LAA% was not (Figure). Conclusion: Reduction of η and RBC/tissue is consistent with a loss of functional pulmonary capillaries in IPAH-low. Alveolar microstructure destruction must be considered as contributing factor as evidenced by elevated 129Xe ADC, which seems more sensitive for emphysema than LAA%.
- Open Access
- 1 September 2023
- Published by Elsevier in Zeitschrift für Medizinische Physik
- Vol. 35 (1) , 33-45
Compartment-specific 129Xe HyperCEST z spectroscopy and chemical shift imaging of cucurbit[6]uril in spontaneously breathing rats
- 1 September 2023
- Published by Elsevier in Zeitschrift für Medizinische Physik
- Vol. 35 (1) , 33-45
Open AccessCompartment-specific 129Xe HyperCEST z spectroscopy and chemical shift imaging of cucurbit[6]uril in spontaneously breathing rats
- 29 December 2022
- Published by Wiley in Journal of Magnetic Resonance Imaging
- Vol. 58 (3) , 949-950
Editorial for “Intra‐ and Inter‐visit Repeatability of 129Xenon Multiple‐Breath Washout MRI in Children With Stable Cystic Fibrosis Lung Disease”
- 29 December 2022
- Published by Wiley in Journal of Magnetic Resonance Imaging
- Vol. 58 (3) , 949-950
Editorial for “Intra‐ and Inter‐visit Repeatability of 129Xenon Multiple‐Breath Washout MRI in Children With Stable Cystic Fibrosis Lung Disease”